Lorlatinib

Lorlatinib (ロルラチニブ)

一行要約

Macrocyclic 3rd-gen ALK-TKI (PF-06463922)。CROWN trial の 5 年更新 (Solomon et al. JClinOncol 2024) で mPFS 未到達・5-yr PFS 60% (HR 0.19) を達成し、固形腫瘍 targeted therapy 史上最長の単剤 PFS を記録した。前臨床では Zou et al. CancerCell 2015 / Zou et al. ProcNatlAcadSciUSA 2015 が 1st / 2nd-gen ALK-TKI 全 known resistance mutation (G1202R 含む) に活性を保持する broad spectrum coverage を示した。BBB 透過性に極めて優れ、intracranial ORR 82%・CNS 新規病変累積発生率 4% (vs crizotinib 39%) で CNS prophylaxis 効果を確立。高脂血症 (70%) / 認知機能障害 (20-30%) / 気分変容 (15%) の neurocognitive AE 管理が長期投与の主要課題であり、sequential ALK-TKI strategy における 1L vs 2L+ 後の positioning が臨床的議論の焦点である。

主要エビデンス

1L ALK+ NSCLC (CROWN)

• CROWN primary (Shaw et al. NEnglJMed 2020) : Lorlatinib 100 mg/day vs Crizotinib 250 mg bid、296 例の treatment-naive ALK+ advanced NSCLC。12-mo PFS 78% vs 39% (HR 0.28, 95% CI 0.19-0.41)、ORR 76% vs 58%。Intracranial ORR (measurable disease) : 82% vs 23% → BBB penetration を clinical レベルで決定的に実証。Lorlatinib の 1L superiority を確立
• CROWN 5-yr update (Solomon et al. JClinOncol 2024) : 5-yr PFS 60% vs 8% (HR 0.19, 95% CI 0.13-0.27)、mPFS 未到達 vs 9.3 mo → 固形腫瘍 targeted therapy 史上最長の単剤 PFS。5-yr OS rate は両群とも high (lorlatinib 有意に superior)。Intracranial time to progression: 累積 CNS 新規病変発生率 4% (lorlatinib) vs 39% (crizotinib) → CNS prophylaxis 効果も確立。EML4-ALK variant 3 / TP53 co-mutation 等の high-risk subgroup でも持続的 benefit
• ALEX comparator context: ALEX study (Alectinib vs Crizotinib, Peters et al. NEnglJMed 2017) は mPFS 34.8 mo (alectinib、Mok et al. AnnOncol 2020)。J-ALEX (Hida et al. Lancet 2017) も alectinib 優位を confirm。CROWN の mPFS 未到達は ALEX を大幅に上回る間接比較だが、直接 head-to-head は未実施

2L+ ALK-TKI 後 (resistance rescue)

• Phase 2 cohort (Solomon et al. LancetOncol 2018) : 5 cohort の phase 2 basket study。Prior 2nd-gen ALK-TKI (alectinib / ceritinib) 後の cohort で ORR 39.6%、intracranial ORR 56.1% → 2nd-gen ALK-TKI 耐性後の rescue 有効性を確立。Phase 1 は Shaw et al. LancetOncol 2017 が first-in-human safety + activity を報告 (推奨 phase 2 dose 100 mg/day)
• ALK mutation 別 efficacy (Shaw et al. JClinOncol 2019) : 2L+ lorlatinib 投与例で ALK resistance mutation profiling と efficacy の correlation を解析。G1202R 陽性例で ORR 62% (vs ALK mutation 陰性 ORR 32%) → ALK mutation 検出 (liquid biopsy / rebiopsy) が lorlatinib 治療決定の biomarker として有用。G1202R は alectinib / ceritinib / brigatinib の共通 achilles heel → lorlatinib の unique selling point
• Intracranial efficacy (Felip et al. AnnOncol 2021) : 2nd-gen ALK-TKI 既治療の CNS mets 症例に lorlatinib、intracranial ORR 56%、intracranial mDOR 14.5 mo → CNS rescue としての lorlatinib の value

Alectinib / Brigatinib との比較

比較軸	Lorlatinib (3rd-gen)	Alectinib (2nd-gen)	Brigatinib (2nd-gen)
1L mPFS	未到達 (CROWN 5y, HR 0.19)	34.8 mo (ALEX updated)	24.0 mo (ALTA-1L)
CNS ORR	82% (1L)	81% (ALEX)	78% (ALTA-1L)
G1202R activity	有効 (ORR 62%)	耐性	耐性
CNS 新規病変	4% (5yr)	9% (ALEX)	9% (ALTA-1L)
主要 AE	高脂血症 70%、CNS toxicity	便秘、CPK上昇	ILD (early-onset)、高血圧
長期投与適合性	neurocognitive AE 管理必要	良好	ILD risk

Alectinib は ALEX (Peters et al. NEnglJMed 2017) / J-ALEX (Hida et al. Lancet 2017) / ALESIA (Zhou et al. LancetRespirMed 2019) で 1L efficacy を確立。CNS efficacy は Gadgeel et al. AnnOncol 2018 が ALEX CNS analysis として詳報。

Brigatinib は ALTA-1L (Camidge et al. NEnglJMed 2018、Camidge et al. JThoracOncol 2021) で 1L efficacy を示したが、early-onset pulmonary events (Ng et al. JThoracOncol 2020) が concern。2L+ では ALTA (Kim et al. JClinOncol 2017)、J-ALTA (Nishio et al. JThoracOncol 2021) が alectinib 後の rescue data を蓄積。

ROS1+ NSCLC

• Solomon et al. LancetOncol 2018 (ROS1 cohort) : Crizotinib 既治療含む ROS1+ NSCLC で ORR 36%、intracranial ORR 64%。ROS1 G2032R rescue は限定的
• Lin et al. ClinCancerRes 2021: Crizotinib / lorlatinib 耐性 ROS1+ NSCLC の resistance mechanism を体系的に解析。ROS1 compound mutation (G2032R + L2086F 等) が lorlatinib 耐性の主要 mechanism → lorlatinib の ROS1 rescue value は一部の mutation pattern に限定
• Repotrectinib (Drilon et al. NEnglJMed 2024) 登場後: Repotrectinib が G2032R を含む ROS1 mutation coverage で lorlatinib を上回り、ROS1+ NSCLC の preferred option に → lorlatinib の ROS1 niche は縮小

耐性メカニズム

ALK-TKI resistance の全体像は Rotow et al. NatRevCancer 2017 / Lin et al. CancerDiscov 2017 が包括的に整理:

On-target (ALK mutation)

• Single ALK mutation: G1202R (solvent-front) / L1196M (gatekeeper) / I1171N / F1174L 等が 1st / 2nd-gen ALK-TKI 耐性の主要 mechanism。Gainor et al. CancerDiscov 2016 が ALK mutation spectrum と各世代 TKI の感受性 pattern を体系化
• Compound ALK mutation (lorlatinib 耐性の核心) : Sequential ALK-TKI 使用 (1st → 2nd → 3rd-gen) で compound mutation (2 個以上の mutation 同一 allele 共存) が選択される。Yoda et al. CancerDiscov 2018 が in vitro + 臨床検体で lorlatinib 耐性 compound mutation (G1202R + L1196M / G1202R + G1269A / G1202R + L1198F 等) を同定。これら compound mutation は lorlatinib の binding pocket を構造的に歪め、binding affinity を著減させる
• L1198F resensitization (Shaw et al. NEnglJMed 2016) : Lorlatinib 耐性として出現した L1198F mutation が、paradoxically に crizotinib binding を改善 → crizotinib に resensitize。Sequential mutation evolution の中で “circular TKI recycling” の概念実証。臨床的にこの患者は crizotinib re-challenge で response を示した
• Recondo et al. ClinCancerRes 2020 / Recondo et al. ClinCancerRes 2020: Lorlatinib resistance の spectrum を 42 例の clinical cohort で解析。On-target compound mutation 30%、off-target bypass activation 30%、unknown 40% → lorlatinib 耐性は heterogeneous

Off-target (bypass / non-mutation)

• MET amplification: ALK-TKI 耐性の主要 bypass pathway。Dagogo-Jack et al. ClinCancerRes 2020 が ALK+ NSCLC における MET-driven resistance を systematic に報告
• EMT (Epithelial-Mesenchymal Transition) : Fukuda et al. CancerRes 2019 が ALK mutation status に independent な EMT-mediated resistance を実証 → ALK-TKI + EMT reversal agent の combination rationale
• SHP2 pathway: Dardaei et al. NatMed 2018 が SHP2 阻害で ALK-TKI 感受性を restore することを示した → SHP2 inhibitor + ALK-TKI 併用の preclinical evidence
• On- and off-target の共存: Redaelli et al. CancerRes 2018 が lorlatinib 耐性の preclinical model で on-target mutation + off-target bypass の同時出現を報告 → single rescue strategy では不十分

EML4-ALK variant と治療効果

• Lin et al. JClinOncol 2018: EML4-ALK variant 3 (short variant, v3a/b) が variant 1 (long variant) と比較して ALK-TKI 耐性出現が早い / G1202R mutation 頻度が高い / PFS shorter の “high-risk” variant であることを示した
• Woo et al. AnnOncol 2017: ALK fusion variant の protein stability が異なり、各 ALK-TKI への感受性 pattern に影響
• CROWN variant analysis: CROWN 5-yr data では variant 3 subgroup でも lorlatinib は durable benefit を示す → 1L lorlatinib は high-risk variant を含む全 variant に有効 (alectinib 1L + variant 3 では early progression の懸念が残る)

メカニズム

Macrocyclic structure と ALK binding

PF-06463922 (Lorlatinib) は macrocyclic lactam scaffold を持つ unique な化合物で、rigidified structure が ALK kinase domain の ATP-binding pocket に optimal な binding geometry を実現する (Zou et al. CancerCell 2015) :

• G1202R coverage: G1202R は ALK kinase domain の solvent-front に位置する mutation で、crizotinib / alectinib / ceritinib / brigatinib の binding を steric に阻害する 2nd-gen TKI の共通 achilles heel。Lorlatinib の macrocyclic scaffold は G1202R の steric hindrance を回避する compact な binding mode を採用 → IC50 維持
• ALK / ROS1 dual selectivity: ALK と ROS1 は kinase domain の ATP-binding pocket 構造が高度に conserved → lorlatinib は ALK IC50 約1 nM / ROS1 IC50 約1 nM の dual potency を示す。Zou et al. ProcNatlAcadSciUSA 2015 が ROS1 mutation panel への activity を in vitro で confirm
• Compound mutation の限界: L1196M + G1202R 等の compound mutation では macrocyclic ring の flexibility が不足し binding affinity が低下 → 4th-gen ALK-TKI (TPX-0131 / NVL-655) はこの限界を macrocyclic + extended pharmacophore で克服する設計

BBB penetration

Lorlatinib の CNS efficacy は exceptional で、pharmacological basis は:

• P-glycoprotein (P-gp) 非基質: Lorlatinib は P-gp / BCRP (BBB efflux transporter) の substrate ではない → BBB efflux を回避して CNS に高濃度で到達
• CNS unbound concentration: Brain-to-plasma unbound concentration ratio 約0.75 (非常に高い)。比較: Alectinib 約0.2-0.4 (moderate) / Crizotinib 約0.06 (poor) / Brigatinib 約0.3
• Clinical CNS data: CROWN で intracranial ORR 82% (measurable disease)、5-yr CNS 新規病変 cumulative incidence 4% → 事実上の CNS prophylaxis。ALK+ NSCLC は CNS metastasis 高リスク (lifetime risk 30-50%) であり、BBB-penetrant 1L TKI の CNS protection は OS に直結する

Sequential ALK-TKI strategy

ALK+ NSCLC は sequential TKI strategy で長期生存が可能な “chronic disease” model:

• 1st → 2nd → 3rd-gen sequence: Crizotinib → Alectinib → Lorlatinib の historical sequence で total TKI exposure period が 5-10 年に及ぶ例がある (Asao et al. ClinLungCancer 2017)
• 1L lorlatinib の “sequence disruption”: CROWN の結果は 1L lorlatinib で 5-yr PFS 60% → 2nd-gen TKI を sequence 上 skip して直接 3rd-gen を 1L に使用する戦略。ただし、lorlatinib 耐性後の 2nd-gen TKI rescue は compound mutation pattern 依存 (L1198F 出現時のみ crizotinib が有効: Shaw et al. NEnglJMed 2016)
• Post-lorlatinib salvage: Lorlatinib 耐性後の treatment option は limited。Platinum + Pemetrexed (Lin et al. JThoracOncol 2020 が 2nd-gen 耐性後 chemo data を報告) / 4th-gen ALK-TKI / IO + chemo の exploratory use

臨床位置づけ

• 1L ALK+ NSCLC: CROWN に基づき Lorlatinib が NCCN preferred 1L standard (Category 1)。特に CNS mets existing / high CNS risk / EML4-ALK variant 3 / TP53 co-mutation (high-risk subgroup) に first choice。G1202R を含む全 known mutation への broad spectrum coverage が 1L use の theoretical advantage (PFS on 1L で mutation selection を最大限遅延)
• 1L Alectinib vs Lorlatinib の臨床判断: Direct head-to-head なし。Lorlatinib は PFS で superior (mPFS 未到達 vs 34.8 mo) だが、neurocognitive AE (word-finding difficulty / mood effects / cognitive slowing) が 1L long-term use で quality of life に影響。Alectinib は tolerance 良好で long-term 投与に適する → AE tolerance / patient preference / CNS risk に基づく individualized 1L 選択が実践的
• Post-2nd-gen ALK-TKI rescue: Alectinib / Brigatinib / Ceritinib 耐性後の lorlatinib は G1202R+ 例で ORR 62% (Shaw et al. JClinOncol 2019)。ALK mutation 検出 (cfDNA / rebiopsy) による patient selection が推奨。ALK mutation 陰性の off-target resistance では lorlatinib benefit は限定的
• 毒性管理の実際:
• 高脂血症 (grade any 70%, grade 3-4 20%) : Total cholesterol / triglyceride 上昇 → statin + fibrate が first-line 管理。心血管 long-term risk のモニタリング必須
• 認知機能障害 (20-30%) : Word-finding difficulty / processing speed 低下 / concentration impairment。Grade 1 では continuation / grade 2 で dose reduction (75 mg) / grade 3 で hold
• 気分変容 (15%) : Mood lability / irritability / depression。CNS 直接 effect vs reactive → psychiatric evaluation が必要な例あり
• 体重増加 (20%) : Central adiposity + metabolic syndrome pattern
• 末梢神経障害: Mild、dose-limiting にはなりにくい
• 長期投与の chronic disease model: CROWN 5-yr data で 5 年以上の continuous dosing が実証 → ALK+ NSCLC を “chronic disease” (HIV parallel) として management する paradigm。Lorlatinib の 5-yr PFS 60% は EGFR-mutant NSCLC の osimertinib (FLAURA mPFS 18.9 mo) を大幅に上回る exceptional outcome

Open Questions

• 1L Lorlatinib vs Alectinib head-to-head: 直接比較試験は計画されていない。CROWN (mPFS 未到達) vs ALEX (34.8 mo) の cross-trial comparison は confounded。Biomarker-guided 1L 選択 (CNS mets → lorlatinib / no CNS + good tolerance priority → alectinib / EML4-ALK v3 or TP53 co-mut → lorlatinib) の prospective validation が必要
• Compound mutation rescue (4th-gen ALK-TKI) : G1202R + L1196M / G1202R + G1269A 等の compound mutation は lorlatinib resistant → 4th-gen ALK-TKI (TPX-0131 / NVL-655) の clinical development が compound mutation era の bridge。Phase I data 待ち
• Post-1L-lorlatinib treatment sequence: 1L lorlatinib 耐性後に 2nd-gen ALK-TKI re-challenge が有効か? Compound mutation pattern 依存 (L1198F → crizotinib resensitization のような例は rare)。Chemo + IO / 4th-gen TKI / clinical trial が realistic option
• Off-target resistance の克服: MET amplification → MET-TKI 併用 / SHP2 pathway → SHP2 inhibitor (Dardaei et al. NatMed 2018) / EMT → 機序不明な点が多い → combination approach の preclinical → clinical translation
• CNS toxicity の long-term management: 5 年以上の chronic 投与での cognitive / mood AE の蓄積性 assessment。Neuropsychological testing の standardization / dose modification guide の precision 化。QoL trade-off の patient-reported outcome 研究
• ROS1+ NSCLC での residual role: Repotrectinib (Drilon et al. NEnglJMed 2024) が G2032R coverage で lorlatinib を上回る。Lorlatinib の ROS1 rescue niche は repotrectinib 耐性後 / repotrectinib non-eligible に限定
• 小児 ALK-driven 腫瘍: ALK+ neuroblastoma / inflammatory myofibroblastic tumor (IMT) での lorlatinib 適応拡大 (Infarinato et al. CancerDiscov 2016 が neuroblastoma preclinical data を報告)。Pediatric formulation 開発と NANT consortium 試験の progress
• Perioperative ALK-TKI: Resectable ALK+ NSCLC での neoadjuvant / adjuvant lorlatinib の phase III 試験 (ALINA-2 等) → adjuvant alectinib (ALINA: alectinib adjuvant IA-IIIA ALK+) との positioning

重要論文 Top 10

1. ★★★★★ Solomon et al. JClinOncol 2024 — CROWN 5-yr — mPFS 未到達、固形腫瘍史上最長 PFS
2. ★★★★★ Shaw et al. NEnglJMed 2020 — CROWN primary — 1L superiority、intracranial ORR 82%
3. ★★★★★ Solomon et al. LancetOncol 2018 — Phase 2 cohort — 2L+ resistance rescue 証明
4. ★★★★ Shaw et al. JClinOncol 2019 — ALK mutation profiling-guided efficacy (G1202R+ ORR 62%)
5. ★★★★ Yoda et al. CancerDiscov 2018 — Compound mutation selection — lorlatinib 耐性の核心

関連エンティティ

• Drug class: ALK-TKI
• 標的遺伝子: ALK, ROS1
• 競合: Alectinib, Brigatinib (2nd-gen)
• 耐性関連: G1202R, compound mutation
• 試験: CROWN
• Concept: ALK-TKI-resistance
• ドメイン: lung-cancer-treatment

関連論文

直近 30 件のみ表示中 (関連 134 件)。 全件は MOC ページ または Obsidian (source Markdown) から辿れます。

Basic-Brain metastasis

• Mavrikios et al. AnnOncol 2026 — Lung cancer brain metastases management at the dawn of personalized medicine are we ready to break the barriers

Basic-Neutrophil and myeloid cell

• Wu et al. FrontImmunol 2026 — Tumor-associated neutrophils in pancreatic ductal adenocarcinoma mechanisms and therapeutic targeting
• Raskov et al. Oncogenesis 2022 — Neutrophils and polymorphonuclear myeloid-derived suppressor cells an emerging battleground in cancer therapy

Basic-Oncogene and genetics

• Scaparone et al. CancerDiscov 2026 — EML4-ALK mediates resistance to KRAS G12C inhibition and induces an
• Li et al. JThoracOncol 2021 — Potential unreliability of uncommon ALK, ROS1, and RET genomic breakpoints in predicting the efficacy of targeted

Basic-Tumor microenvironment

• Hu et al. CancerCell 2021 — Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms

Clinical-Epidemiology

• Thai et al. Lancet 2021 — Lung Cancer

Clinical-Methodology

• Spreafico et al. CancerDiscov 2021 — The future of clinical trial design in oncology

Clinical-NEC

• Heijboer et al. JCOPrecisOncol 2025 — Actionable genomic alterations in large cell neuroendocrine carcinoma A european case series of patients treated with a

Clinical-NSCLC-ALK

• Mok et al. AnnOncol 2020 — Updated overall survival and final progression-free survival data for patients with treatment-naive advanced
• Felip et al. AnnOncol 2021 — Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer
• Dagogo-Jack et al. ClinCancerRes 2020 — MET alterations are a recurring and actionable resistance mechanism in ALK-positive lung cancer
• Recondo et al. ClinCancerRes 2020 — Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer
• Tanimoto et al. ClinCancerRes 2021 — Proteasome inhibition overcomes ALK-TKI resistance in ALK-RearrangedTP53-mutant NSCLC via noxa expression
• Ito et al. EurJCancer 2021 — Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma
• Kim et al. FutureOncol 2021 — ALTA-2 phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed
• Mascarenhas et al. JCOGlobOncol 2026 — Current access to anaplastic lymphoma kinase testing and targeted therapies for non-small cell lung cancer in brazil
• Solomon et al. JClinOncol 2024 — Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer 5-year outcomes from the
• Nishio et al. JThoracOncol 2021 — Brigatinib in japanese patients with ALK-positive NSCLC previously treated with alectinib and other tyrosine kinase
• Naito et al. JpnJClinOncol 2021 — Brigatinib and lorlatinib their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous

Clinical-NSCLC-Driver negative

• Wang et al. NatMed 2021 — Toward personalized treatment approaches for non-small-cell lung cancer

Clinical-NSCLC-ROS1

• Ma et al. CancerCell 2026 — JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1G2032R resistance mutation in NSCLC
• DAngelo et al. Cancers 2020 — Focus on ROS1-positive non-small cell lung cancer (NSCLC) crizotinib, resistance mechanisms and the newer generation of
• Papadopoulos et al. ClinCancerRes 2020 — U.S. phase I first-in-human study of taletrectinib (DS-6051bab-106), a ROS1TRK inhibitor, in patients with advanced
• Lin et al. ClinCancerRes 2021 — Spectrum of mechanisms of resistance to crizotinib and lorlatinib in ROS1 fusion-positive lung cancer
• Almquist et al. JCOOncolPract 2021 — The road less traveled A guide to metastatic ROS1-rearranged non-small-cell lung cancer
• Dziadziuszko et al. JClinOncol 2021 — Updated integrated analysis of the efficacy and safety of entrectinib in locally advanced or metastatic ROS1
• Ou et al. JTOClinResRep 2021 — Efficacy of taletrectinib (AB-106ds-6051b) in ROS1+ NSCLC an updated pooled analysis of U.S. and japan phase 1 studies
• Itchins et al. LungCancer 2026 — Real-world treatment sequencing and survival in ROS1-rearranged NSCLC across evolving treatment eras findings from the
• Drilon et al. NEnglJMed 2024 — Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer